Clarity Pharmaceuticals' Cu-64 SAR-bisPSMA Doubles Prostate Cancer Detection in Head-to-Head Trial
Event summary
- Clarity Pharmaceuticals' Cu-64 SAR-bisPSMA detected 2.6x more prostate cancer lesions per patient than Ga-68 PSMA-11 in a head-to-head trial.
- The study, led by Prof Louise Emmett at St Vincent's Hospital Sydney, involved 50 patients with biochemical recurrence of prostate cancer.
- Cu-64 SAR-bisPSMA identified prostate cancer in 78% of patients compared to 36% with Ga-68 PSMA-11.
- Planned patient management changed for 44% of trial participants following Cu-64 SAR-bisPSMA PET/CT assessment.
- Findings will be presented orally at the European Association of Urology (EAU) Congress 2026 in London.
The big picture
Clarity Pharmaceuticals' Cu-64 SAR-bisPSMA represents a significant advancement in prostate cancer diagnostics, addressing the low sensitivity of current PSMA PET agents. The $2 billion US PSMA PET imaging market is dominated by agents with limited ability to detect cancer, particularly at low PSA levels. This trial positions Cu-64 SAR-bisPSMA as a potential game-changer, with the ability to improve early intervention and patient outcomes. The upcoming presentation at the EAU Congress 2026 will further validate these findings and solidify its position in the market.
What we're watching
- Regulatory Pathway
- Whether Clarity Pharmaceuticals can leverage these results to secure FDA approval and become the new standard of care in PSMA PET imaging.
- Market Disruption
- The pace at which Cu-64 SAR-bisPSMA can capture market share from existing PSMA PET agents like Ga-68 PSMA-11 and 18F-DCFPyL.
- Clinical Adoption
- How quickly clinicians will integrate Cu-64 SAR-bisPSMA into treatment protocols, given its superior detection capabilities.
Related topics